IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
High Grade Ovarian Serous Adenocarcinoma
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the High Grade Ovarian Serous Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Roswell Park Cancer Institute | Phase 2 | BB |
Epirubicin Roswell Park Cancer Institute | Phase 2 | BB |
Nivolumab pharmaand GmbH | Phase 2 | B |
Niraparib Sunnybrook Health Sciences Centre | Phase 2 | B |
Ipilimumab TCR2 Therapeutics | Phase 1/2 | CCC |
View all 18 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →